Identification of a rare polymorphism in the human TP53 promoter

被引:4
|
作者
Attwooll, CL
McGown, G
Thorncroft, M
Stewart, FJ
Birch, JM
Varley, JM
机构
[1] Paterson Inst Canc Res, CRC Dept Canc Genet, Manchester M20 4BX, Lancs, England
[2] Belfast City Hosp, No Ireland Reg Genet Serv, Belfast BT9 7AB, Antrim, North Ireland
[3] Royal Manchester Childrens Hosp, CRC Paediat & Familial Canc Res Grp, Manchester M27 1HA, Lancs, England
基金
英国医学研究理事会;
关键词
D O I
10.1016/S0165-4608(01)00649-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The majority of families with classic Li-Fraumeni Syndrome (LFS) and a significant proportion of Li-Fraumeni-like (LFL) families have a germline mutation in the TP53 tumor suppressor gene. However around 20% of LFS and 60% of LFL families have no identifiable genetic defect in the coding region or splice junctions of TP53, and the genetic basis for cancer susceptibility in these families remains largely uncharacterized. To determine whether promoter mutations could be responsible for the Li-Fraumeni phenotype, we sequenced the TP53 promoter in index cases from members of classic LFS and LFL families without detectable TP53 mutations. We identified an identical single nucleotide deletion within the C/EBP-like site of the promoter in two out of eighteen such families (11%), compared to only one of a total of 366 control samples (0.3%). Although this result is highly significant (P=0.006, Fischer's exact test), the mutation did not affect the expression of TP53 in our hands. We provide evidence that this site is not utilized in the wild type TP53 promoter and further, that mutation of this site in LFS/LFL does not have a functional effect. We conclude that the sequence variant is a rare polymorphism arising within the TP53 promoter. However, the significantly increased frequency of this variant in LFS/LFL remains intriguing. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:165 / 172
页数:8
相关论文
共 50 条
  • [41] TP53 polymorphism, HPV infection, and risk of cervical cancer
    Klug, SJ
    Wilmotte, R
    Santos, C
    Almonte, M
    Herrero, R
    Guerrero, I
    Caceres, E
    Peixoto-Guimaraes, D
    Lenoir, G
    Hainaut, P
    Walboomers, JMM
    Muñoz, N
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2001, 10 (09) : 1009 - 1012
  • [42] ALTERATIONS OF THE TP53 GENE IN HUMAN GLIOMAS
    RASHEED, BKA
    MCLENDON, RE
    HERNDON, JE
    FRIEDMAN, HS
    FRIEDMAN, AH
    BIGNER, DD
    BIGNER, SH
    CANCER RESEARCH, 1994, 54 (05) : 1324 - 1330
  • [43] TP53 family members and human cancers
    Bénard, J
    Douc-Rasy, S
    Ahomadegbe, JC
    HUMAN MUTATION, 2003, 21 (03) : 182 - 191
  • [44] TP53: a key gene in human cancer
    Guimaraes, DP
    Hainaut, P
    BIOCHIMIE, 2002, 84 (01) : 83 - 93
  • [45] TP53 mutations in human skin cancers
    Giglia-Mari, G
    Sarasin, A
    HUMAN MUTATION, 2003, 21 (03) : 217 - 228
  • [46] TP53, TP53 Target Genes (DRAM, TIGAR), and Autophagy
    Hu, Wanglai
    Chen, Song
    Thorne, Rick F.
    Wu, Mian
    AUTOPHAGY: BIOLOGY AND DISEASES: BASIC SCIENCE, 2019, 1206 : 127 - 149
  • [47] PCR DETECTION OF A BGLII POLYMORPHISM IN INTRON-I OF THE HUMAN P53 GENE (TP53)
    WILLEMS, PMW
    MEYERINK, JPP
    VANDELOCHT, LTF
    SMETSERS, TFCM
    DEVRIES, N
    MENSINK, EJBM
    NUCLEIC ACIDS RESEARCH, 1992, 20 (05) : 1172 - 1172
  • [48] Identification of nonsynonymous TP53 mutations in hydatidiform moles
    Chan, Ka-Kui
    Wong, Esther Shuk-Ying
    Wong, Oscar Gee-Wan
    Ngan, Hextan Yuen-Sheung
    Cheung, Annie Nga-Yin
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2018, 809 : 20 - 23
  • [49] Identification of the osteopontin gene as a direct target of TP53
    Morimoto, I
    Sasaki, Y
    Ishida, S
    Imai, K
    Tokino, T
    GENES CHROMOSOMES & CANCER, 2002, 33 (03): : 270 - 278
  • [50] Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations
    Soussi, T
    Kato, S
    Levy, PP
    Ishioka, C
    HUMAN MUTATION, 2005, 25 (01) : 6 - 17